Drug Discovery

Parvus and Resilience expand partnership to develop IBD drug candidate

Clinical-stage company Parvus Therapeutics has expanded its collaboration with biomanufacturing company National Resilience to develop and manufacture the autoimmune drug candidate, PVT401, for inflammatory bowel disease (IBD).

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.

insitro collaborates with Lilly on metabolic disease treatments

Machine learning-enabled drug discovery and development company insitro has executed three agreements with Lilly to advance new treatments for metabolic diseases.

PsychoGenics secures NIH contract to identify new pain therapeutics

Preclinical contract research organisation (CRO) PsychoGenics has received an award from the US National Institutes of Health (NIH) to conduct the testing and identification of new investigational therapeutics aimed at treating pain.

AstraZeneca to license CSPC Pharmaceutical’s lipid-lowering therapy

AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.

FDA grants fast track designation for Elevation Oncology’s EO-3021

The US Food and Drug Administration (FDA) has granted fast track designation for Elevation Oncology’s EO-3021, a treatment for patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer.

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

ENCell has entered into a strategic alliance and licencing agreement with Lucy Biotech for EN001, a next-generation mesenchymal stem cell therapy.

Osivax and KM Biologics sign deal for influenza vaccine in Japan

France-based biopharmaceutical company Osivax has entered into an exclusive license option agreement with Japanese vaccine manufacturer KM Biologics for a broad-spectrum “universal” influenza vaccine candidates in Japan.

Superluminal Medicines secures $120m in Series A funding round

Superluminal Medicines secured $120m in a Series A funding round to advance the development of its assets into clinical trials.